We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Advancis Pharmaceutical has completed enrollment ahead of schedule in the company's
pediatric Amoxicillin PULSYS Phase III clinical trial for the treatment of pharyngitis/tonsillitis
due to Group A streptococcal infections.
Adventrx Pharmaceuticals has received clearance from the FDA under a special
protocol assessment to initiate a Phase III pivotal clinical trial with CoFactor
for the treatment of metastatic colorectal cancer.
Par Pharmaceutical Companies' wholly owned subsidiary, Kali Laboratories has
received final approval from the FDA for its abbreviated new drug application
(ANDA) for tramadol HCl and acetaminophen tablets.
AEterna Zentaris has established a new research collaboration with Wurzburg/Germany-based
Julius-Maximilians- University on the development of tumor vaccines based on
attenuated bacterial carriers.
Guilford Pharmaceuticals has met with the FDA and reached an agreement on a
revised clinical development strategy for the company's lead product candidate,
Aquavan injection (GPI 15715), a novel sedative/hypnotic being developed for
use in procedural sedation.
Transkaryotic Therapies has announced that the last patient has completed treatment
in its open-label Phase I/II clinical trial evaluating its investigational enzyme
replacement therapy for Gaucher disease, gene-activated glucocerebrosidase,
or GA-GCB.